Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 17, Pages 4136-4146
Publisher
American Society of Hematology
Online
2020-09-04
DOI
10.1182/bloodadvances.2020002003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of a new intravenous immunoglobulin (Panzyga® ) in chronic immune thrombocytopenia
- (2019) O. Arbach et al. TRANSFUSION MEDICINE
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
- (2019) James F. Howard et al. NEUROLOGY
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
- (2019) Adrian C. Newland et al. AMERICAN JOURNAL OF HEMATOLOGY
- Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses
- (2019) L. J. Blumberg et al. Science Advances
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
- (2018) James Bussel et al. AMERICAN JOURNAL OF HEMATOLOGY
- 538 FcRn blockade with SYNT001 for the treatment of pemphigus
- (2018) V.P. Werth et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Emerging Concepts in Immune Thrombocytopenia
- (2018) Maurice Swinkels et al. Frontiers in Immunology
- M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
- (2018) Leona E. Ling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Health-related quality of life in adult primary immune thrombocytopenia
- (2018) Hanna Gran Sestøl et al. Expert Review of Hematology
- The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
- (2017) Peter Kiessling et al. Science Translational Medicine
- Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
- (2017) Anne Zufferey et al. Journal of Clinical Medicine
- Current Management of Primary Immune Thrombocytopenia
- (2015) Drew Provan et al. ADVANCES IN THERAPY
- Antibody binding to megakaryocytesin vivoin patients with immune thrombocytopenia
- (2015) Donald M Arnold et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro
- (2015) M. Iraqi et al. HAEMATOLOGICA
- Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange
- (2015) Atsushi Ohkubo et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro
- (2015) M. Iraqi et al. HAEMATOLOGICA
- Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
- (2013) F. Rodeghiero et al. BLOOD
- Therapeutic plasma exchange: A technical and operational review
- (2013) Andre A. Kaplan JOURNAL OF CLINICAL APHERESIS
- A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
- (2011) J. B. Bussel et al. BLOOD
- The ITP syndrome: pathogenic and clinical diversity
- (2009) D. B. Cines et al. BLOOD
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
- (2009) James B Bussel et al. LANCET
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
- (2008) J. B. Bussel et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More